大肠癌根治术后5年生存率一直徘徊在45％—55％之间,治疗失败的主要原因是复发和转移。其中50％的病人发生肝转移,而使病人近期死亡。门静脉5—Fu化疗自应用以来,受到各国学者广泛重视,本文就有关问题综述如下。1 研究概况 有关门静脉5—Fu化疗预防大肠癌肝转移的研究始于50年代。当时多数外科医生认为肿瘤侵犯至肠系膜静脉及术中处理肿瘤将引起癌细胞经血行播散至门静脉,这些癌细胞被纤维素和血小板包裹, The 5-year survival rate of patients with colorectal cancer has been hovering between 45% -55%, the main reason for treatment failure is recurrence and metastasis. Of these, 50% of patients develop liver metastases, leaving the patient dead in the near future. Since the application of portal vein 5-Fu chemotherapy, scholars from all over the world have paid much attention to this issue. 1 Research Overview The portal vein of 5-Fu chemotherapy to prevent liver metastasis of colorectal cancer began in the 50’s. At that time, most surgeons believed that tumor invasion to the mesenteric vein and intraoperative management of the tumor would cause cancer cells to spread to the portal vein by blood, which were surrounded by cellulose and platelets,